File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/jjco/hyn022
- Scopus: eid_2-s2.0-42549151234
- PMID: 18407933
- WOS: WOS:000255439200002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer
Title | Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer |
---|---|
Authors | |
Keywords | Capecitabine Hand-foot syndrome Nasopharyngeal carcinoma Palliative chemotherapy |
Issue Date | 2008 |
Publisher | Oxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/ |
Citation | Japanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249 How to Cite? |
Abstract | background: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. © The Author (2008). Published by Oxford University Press. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/83489 |
ISSN | 2023 Impact Factor: 1.9 2023 SCImago Journal Rankings: 0.612 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chua, D | en_HK |
dc.contributor.author | Wei, WI | en_HK |
dc.contributor.author | Sham, JST | en_HK |
dc.contributor.author | Au, GKH | en_HK |
dc.date.accessioned | 2010-09-06T08:41:39Z | - |
dc.date.available | 2010-09-06T08:41:39Z | - |
dc.date.issued | 2008 | en_HK |
dc.identifier.citation | Japanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249 | en_HK |
dc.identifier.issn | 0368-2811 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/83489 | - |
dc.description.abstract | background: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. © The Author (2008). Published by Oxford University Press. All rights reserved. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Oxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/ | en_HK |
dc.relation.ispartof | Japanese Journal of Clinical Oncology | en_HK |
dc.rights | Japanese Journal of Clinical Oncology. Copyright © Oxford University Press. | en_HK |
dc.subject | Capecitabine | en_HK |
dc.subject | Hand-foot syndrome | en_HK |
dc.subject | Nasopharyngeal carcinoma | en_HK |
dc.subject | Palliative chemotherapy | en_HK |
dc.title | Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0368-2811&volume=38&spage=244&epage=9&date=2008&atitle=Capecitabine+monotherapy+for+recurrent+and+metastatic+nasopharyngeal+cancer. | en_HK |
dc.identifier.email | Chua, D: dttchua@hkucc.hku.hk | en_HK |
dc.identifier.email | Wei, WI: hrmswwi@hku.hk | en_HK |
dc.identifier.authority | Chua, D=rp00415 | en_HK |
dc.identifier.authority | Wei, WI=rp00323 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1093/jjco/hyn022 | en_HK |
dc.identifier.pmid | 18407933 | - |
dc.identifier.scopus | eid_2-s2.0-42549151234 | en_HK |
dc.identifier.hkuros | 141513 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-42549151234&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 38 | en_HK |
dc.identifier.issue | 4 | en_HK |
dc.identifier.spage | 244 | en_HK |
dc.identifier.epage | 249 | en_HK |
dc.identifier.isi | WOS:000255439200002 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Chua, D=7006773480 | en_HK |
dc.identifier.scopusauthorid | Wei, WI=7403321552 | en_HK |
dc.identifier.scopusauthorid | Sham, JST=7101655565 | en_HK |
dc.identifier.scopusauthorid | Au, GKH=7003748615 | en_HK |
dc.identifier.issnl | 0368-2811 | - |